A midstage trial of Vertex Pharmaceuticals' investigational hepatitis C drug VX-135 was placed on partial clinical hold by the FDA. The move was made after three patients treated with 400 milligrams of the drug had elevated levels of liver enzymes. "We are committed to continuing to work closely with the FDA to provide the data needed to support evaluation of a 200 mg dose of VX-135 in the U.S.," said Chief Medical Officer Robert Kauffman of Vertex.

Full Story:

Related Summaries